Ruijin Hospital
872
235
277
128
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.9%
17 terminated/withdrawn out of 872 trials
88.3%
+1.8% vs industry average
12%
101 trials in Phase 3/4
8%
10 of 128 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (872)
STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump
Role: collaborator
An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease
Role: collaborator
Effects of Icosapent Ethyl on Coronary Plaque, Inflammation, and Ventricular Remodeling
Role: lead
Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment
Role: collaborator
Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
Role: lead
MSC-Exosome Therapy for Frontotemporal Dementia
Role: lead
A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
Role: lead
Local Field Potential Correlates of Neuropsychiatric Symptoms in Parkinson's Disease
Role: collaborator
BCI With 40Hz Stimulation in Alzheimer's Disease
Role: lead
Study of SA+X in the Treatment of Newly Diagnosed AML
Role: lead
Safety and Efficacy of Intrathecal NTF001 Injection in ALS
Role: lead
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
Role: lead
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Role: lead
Multicenter Validation of a Risk Prediction Model for MDRGNB Infection
Role: collaborator
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Role: lead
Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation
Role: lead
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Role: lead
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)
Role: collaborator
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
Role: collaborator
LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure
Role: lead